Wang, L. A., Gonzalez, D., Leeder, J. S., Tyndale, R. F., Pearce, R. E., Benjamin, D. K., … Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee, . (2017). Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. J Clin Pharmacol, 57(2), 230–234. https://doi.org/10.1002/jcph.797

Wang, Laura A., Daniel Gonzalez, J Steven Leeder, Rachel F. Tyndale, Robin E. Pearce, Daniel K. Benjamin, Gregory L. Kearns, Michael Cohen-Wolkowiez, and Michael Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. “Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation.” J Clin Pharmacol 57, no. 2 (February 2017): 230–34. https://doi.org/10.1002/jcph.797.

Wang LA, Gonzalez D, Leeder JS, Tyndale RF, Pearce RE, Benjamin DK, et al. Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. J Clin Pharmacol. 2017 Feb;57(2):230–4.

Wang, Laura A., et al. “Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation.” J Clin Pharmacol, vol. 57, no. 2, Feb. 2017, pp. 230–34. Pubmed, doi:10.1002/jcph.797.

Wang LA, Gonzalez D, Leeder JS, Tyndale RF, Pearce RE, Benjamin DK, Kearns GL, Cohen-Wolkowiez M, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. J Clin Pharmacol. 2017 Feb;57(2):230–234.